Effect of somatostatin on meal-induced gastric secretion in duodenal ulcer patients.
The effect of somatostatin, a growth hormone releasing-inhibiting hormone (GH-RIH) on basal and meal-, pentagastrin-, or histamine-stimulated gastric acid and pepsin secretion was studied in six duodenal ulcer patients. Intravenous GH-RIH infused in graded doses ranging from 0.62 to 5.0 microgram/kg/hr produced a dose-related inhibition of pentagastrin-induced acid secretion reaching about 15% of control level at the dose of 5.0 microgram/kg/hr. Acid inhibition was paralleled by a decrease in the pepsin output and accompanied by a dose-dependent reduction in serum growth hormone and insulin levels measured by radioimmunoassay. GH-RIH used in a single dose of 2.5 microgram/kg/hr produced about 85% inhibition of acid secretion induced by a meal (measured by intragastric titration) accompanied by a significant decrease in serum gastrin and insulin levels. The effect of GH-RIH on histamine-stimulated secretion was very modest and observed only after stopping the GH-RIH infusion. Thus GH-RIH suppressed acid and pepsin secretion induced by pentagastrin and a meal, and this effect was accompanied by a suppression of serum growth hormone and gastrin levels which may contribute to the inhibition of gastric secretion observed.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000378:metabolism*; D004435:Eating; D005750:Gastric Juice / Q000378:metabolism*; D005755:Gastrins / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000097:blood; D010418:Pentagastrin / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism; D011863:Radioimmunoassay; D013004:Somatostatin / Q000494:pharmacology*; D013268:Stimulation, Chemical
D005755:Gastrins; D007328:Insulin; D013004:Somatostatin; D006632:Histamine; D013006:Growth Hormone; D010434:Pepsin A; D010418:Pentagastrin